ONA-255 / Ona Therap - LARVOL DELTA

ONA-255-101: A study to investigate the safety and efficacy of ONA-255 in participants with advanced cancer (clinicaltrialsregister.eu) - P1/2 | N=117 | Recruiting | Sponsor: Ona Therapeutics S.L.

New P1/2 trial • Breast Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

REVEAL GENOMICS and Ona Therapeutics Join Forces to Advance Next-generation Cancer Treatment (Businesswire) - "REVEAL GENOMICS and Ona Therapeutics today announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the precision and efficacy of cancer treatment across multiple tumor types....As a leader in genomic innovation, REVEAL GENOMICS will conduct a comprehensive molecular analysis of tumor and blood samples from the ONA-255 phase 1-2 clinical trial as part of this strategic collaboration."

Licensing / partnership • Oncology

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types (PRNewswire) - "Its lead ADC, ONA-255, has broad potential to treat breast, gastric, and other solid tumors, and is advancing through IND-enabling studies to initiate clinical development by the end of 2025. In parallel, Ona is developing ONA-389, a second ADC that is positioned for the treatment of advanced microsatellite stable (MSS) colon and liver cancers. This promising therapeutic is set to begin IND-enabling studies in the second half of 2025."

New trial • Breast Cancer • Colon Cancer • Gastric Cancer • Hepatocellular Cancer